Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: IPH2102 at 1 mg/kgDrug: IPH2102 at 0.1 mg/kgDrug: Placebo (normal saline solution)
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 152
- Registration Number
- NCT01687387
- Locations
- ๐ซ๐ท
Hรดpital Claude Huriez, Lille, France
๐ซ๐ทCHU Angers, Angers, France
๐ซ๐ทCHU d'Amiens, Amiens, France
Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis
- Conditions
- InflammationRheumatoid Arthritis
- Interventions
- Drug: NNC 0141-0000-0100Drug: placebo
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 92
- Registration Number
- NCT01370902
A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 21
- Registration Number
- NCT01256073
- Locations
- ๐ซ๐ท
Hopital Dupuytren, LIMOGES Cedex, France
๐ซ๐ทInstitut Paoli-Calmettes, Marseille, Marseille Cedex 09, France
๐ซ๐ทC.H.R.U. de Nantes - Hotel Dieu, NANTES Cedex 1, France
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT01222286
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
- Conditions
- Patients With Multiple Myeloma Experiencing aFirst or Second Relapse
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT01217203
- Locations
- ๐บ๐ธ
Dana Farber, Boston, Massachusetts, United States
๐บ๐ธNYU Clinical Cancer Center, New York, New York, United States
๐บ๐ธSaint Francis Hospital, Greensville, South Carolina, United States
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 27
- Registration Number
- NCT00999830
- Locations
- ๐ซ๐ท
CHU Nancy, Nancy, France
๐ซ๐ทHopital Saint Louis, Paris, France
๐ซ๐ทInstitut Paoli Calmettes, Marseille, France
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT00552396
- Locations
- ๐บ๐ธ
Ohio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธIndiana University Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธMont Sinai Medical Center, New York City, New York, United States